Spatial Map of Bladder Cancer Reveals Hidden Tumor Environments and New Paths Toward Precision Therapy
Key Insights
Researchers at MD Anderson Cancer Center developed a spatial map of muscle-invasive bladder cancer (search), published in Cancer Discovery, revealing that luminal and basal-like tumor cell states coexist in organized patterns within individual tumors.
Luminal-like tumor cells reside in tumor cores with high FGFR3 (search) and NECTIN4 (search) expression, while basal-like cells occupy invasive margins with elevated EGFR (search) signaling, chromosomal instability, and immune infiltration.
Preclinical models showed NECTIN4 (search) overexpression increased sensitivity to the antibody-drug conjugate enfortumab vedotin, and chemotherapy sensitivity differed by tumor region, supporting spatially informed combination or sequencing strategies.
A team at The University of Texas MD Anderson Cancer Center has constructed a detailed spatial map of muscle-invasive bladder cancer (search) that fundamentally challenges the traditional binary classification of these tumors. Published in Cancer Discovery, the study demonstrates that luminal and basal-like tumor cell states coexist within individual tumors in highly organized spatial patterns, each with distinct therapeutic vulnerabilities and immune microenvironments.
The research was led by Linghua Wang, M.D., Ph.D., professor of Genomic Medicine and executive director of the Center for Cellular Language Intelligence, together with Jianjun Gao, M.D., Ph.D., professor of Genitourinary Medical Oncology. Co-first authors Kai Yu, Ph.D., and Jianfeng Chen, M.D., Ph.D., spearheaded the experimental work.
"Traditional molecular subtyping often classifies bladder cancers as either luminal or basal, but our spatial analyses show that this binary view is incomplete," Wang said. "Within a single patient's tumor, luminal and basal-like programs can coexist in highly organized spatial patterns, and those patterns are closely tied to immune activity, lineage-specific treatment vulnerabilities, and how different tumor regions may respond to treatment."
A Continuous Differentiation Axis Within Tumors
Muscle-invasive bladder cancer (search) is a clinically heterogeneous disease, and current biomarkers do not fully explain the variability in patient responses to treatment. To address this gap, the researchers integrated spatial transcriptomics from 22 pretreatment tumors with matched whole-exome sequencing and bulk RNA sequencing. Single-cell RNA sequencing and single-cell spatial transcriptomics from additional tumors were used to validate findings at higher resolution.
The spatial map revealed that cancer cells transition gradually from luminal to basal-like states along a continuous differentiation axis within individual tumors. Luminal-like tumor cells were predominantly located in tumor cores and were enriched for FGFR3 (search) and NECTIN4 (search) — two clinically relevant therapeutic markers. Conversely, basal-like tumor cells were found more often near invasive tumor margins, where they exhibited higher EGFR (search) signaling, epithelial-mesenchymal transition programs, chromosomal instability, and immune infiltration, all hallmarks of tumor aggressiveness.
"An important message from this work is that effective treatment may need to account for both luminal and basal components within the same tumor, as well as their spatial organization," Gao said. "Rather than treating bladder cancer as a single uniform disease state, spatial information may help guide rational combinations or sequencing of therapies that target distinct tumor regions and cell states."
Lineage-Specific Treatment Vulnerabilities
The study identified actionable, lineage-specific treatment vulnerabilities. Luminal tumor regions showed high NECTIN4 (search) expression, reinforcing NECTIN4 as a relevant therapeutic target in tumors or tumor regions enriched for luminal features. Basal-like regions, by contrast, were associated with immune-rich microenvironments and greater chemotherapy sensitivity.
Preclinical testing confirmed these observations: NECTIN4 (search) overexpression increased sensitivity to enfortumab vedotin — a NECTIN4-targeted antibody-drug conjugate — in vitro and shifted tumor cells toward a more luminal-like state. Chemotherapy and enfortumab vedotin appeared to act through distinct mechanisms, suggesting that spatial information may help inform how therapies are combined or sequenced to address different tumor compartments.
The researchers also established that FGFR3 (search) and EGFR (search) mark opposite ends of the luminal-basal spectrum, providing a practical framework for assessing tumor aggressiveness based on where tumor cells fall along that continuum. FGFR3 was linked to luminal states, while EGFR was enriched in basal-like and more plastic tumor states. These patterns were validated across more than 3,000 tumors from independent bladder cancer cohorts.
Toward Spatially Informed Biomarkers
The findings support the development of spatially informed biomarkers that could help clinicians determine which therapies are most likely to affect specific tumor regions and cell states. For instance, future approaches could evaluate NECTIN4 (search)-directed therapies for immune-cold luminal tumor cores, while chemotherapy or immunotherapy-based treatments may be better suited to target inflamed basal-like margins.
Future studies will need to validate these findings in larger, prospective clinical cohorts, including post-treatment samples, to determine how therapy reshapes tumor architecture over time.